In animal models of Parkinson’s and Alzheimer’s disease, CEF-treated animals showed improvement in memory impairment, downregulation of the tau protein, restoration of cognitive function, and neuronal density [37,38,39]. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.